Unicycive Therapeutics Stock (NASDAQ:UNCY)

Ownership Financials Chart

Previous Close

$0.48

52W Range

$0.20 - $1.82

50D Avg

$0.43

200D Avg

$0.78

Market Cap

$52.87M

Avg Vol (3M)

$1.70M

Beta

2.29

Div Yield

-

UNCY Company Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jul 12, 2021

Website

UNCY Performance

UNCY Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$675.00K	$951.00K	-
Operating Income	$-20.77M	$-18.05M	$-8.98M
Net Income	$-31.41M	$-18.06M	$-10.63M
EBITDA	$-20.77M	$-18.05M	$-8.98M
Basic EPS	-	$-1.20	$-0.91
Diluted EPS	-	$-1.20	$-0.91

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
SQL	SeqLL Inc.
RNAZ	TransCode Therapeutics, Inc.
HILS	Tharimmune, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.